A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT03900598 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Non-Hodgkin

Interventions

DRUG: JNJ-67856633

Sponsor

Janssen Research & Development, LLC